MobiDrop Bio was recognized as a Specialized Small and Medium-sized Enterprise in Zhejiang Province!

Editor:MobiDrop (Zhejiang) Co., Ltd. │ Release Time:2022-12-01 

image.png


Recently, the Department of Economy and Information Technology of Zhejiang Province officially  announced  the  list  of  "Specialized,  Precise  and  New"  enterprises  in  Zhejiang Province for the year 2022, and MobiDrop Biotechnology (Zhejiang) Co. Ltd. was awarded the title  of  "Specialized,  Precise  and  New"  Small  and  Medium  Enterprises  in  Zhejiang Province.


image.png

image.png


The award of "specialized, specialized and new" small and medium-sized enterprises in Zhejiang Province this time is a recognition of MobiDrop Bio's product research and development and innovation capabilities, and a reflection of the comprehensive strength of the enterprise.


Adhering to the development concept of "serving human health with life science", MobiDrop will continue to develop high-throughput,  high-quality and cost-effective platform products based on innovative microfluidic technology and cutting -edge single-cell technology, to take advantage of technological innovation, to promote the technological development of single-cell sequencing in China, to practice "We will continue to improve our core competitiveness by focusing on our products and building bioassay chips with independent intellectual property rights, as well as supporting machines, reagents and software, to empower China's life science and precision medicine with technological innovation.


About MobiDrop

 

Founded in Boston, USA and located in Zhejiang, China, MobiDrop is a group of outstanding talents consisting of international top scientists and executives from multinational medical device  companies. We are committed to empowering scientific research and precision medicine with innovative microfluidic and single-cell sequencing technologies. It has become a leader in research+IVD solutions with key technologies such as microfluidics, sequencing, biochemistry, hardware development, and bioconferencing, and has launched a dual technology platform for single-cell sequencing and digital PCR, developing in parallel in multiple fields such as liquid biopsy, companion diagnostics, and life science research.